Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04830592
Title A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck (MOAT)
Acronym MOAT
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors PsiOxus Therapeutics Ltd
Indications
Therapies
Age Groups: senior | adult
Covered Countries GBR


No variant requirements are available.